Company: PFSA
Filing Date: 2025-04-03
Form Type: S-4/A
Source: 0001213900-25-028544
Chunk: 321

Company: Profusa, Inc.
Filing Date: 2025-04-03
Form: S-4/A
Chunk 321
---
 directors have invested an aggregate of $115,000 into Profusa’s Bridge Notes, which will be converted into shares of Profusa and exchanged for shares of New Profusa Common Stock in connection with the Merger; •NorthView’s directors will not receive reimbursement for all out -of-pocketexpenses incurred by them on NorthView’s behalf incident to identifying, investigating and consummating a business combination, unless a business combination is consummated (as of the date hereof, $22,650 have been incurred); •Up to an aggregate amount of $2,500,000 of any amounts outstanding under any working capital loans made by Sponsor or any of its affiliates to NorthView may be converted into warrants to purchase New Profusa Common Stock at a price of $1.00 per warrant at the option of the lender. As of the date of this proxy statement/prospectus there were no amounts outstanding under such working capital loans, however, the Sponsor held a convertible promissory note in the amount of $1,919,796, convertible at a price of $2.22; •the Sponsor and its affiliates can earn a positive rate of return on their investments, even if the public stockholders experience a negative rate of return on their investments in NorthView and New Profusa; •the potential continuation of certain of NorthView’s directors as directors of New Profusa if the Business Combination is completed; •because Sponsor and the NorthView directors will benefit from the completion of a business combination, they may be incentivized to recommend and complete a business combination of a less favorable target company or on terms less favorable to NorthView stockholders, rather than liquidate NorthView; and •the continued indemnification of current directors and officers of NorthView and the continuation of directors’ and officers’ liability insurance after the Business Combination. In addition, I -Bankersand Dawson James Securities, the managing underwriters of NorthView’s IPO, received an aggregate of 450,000 representative shares of NorthView Common Stock in connection with the IPO. None of those shares will have any value if NorthView fails to complete an initial business combination and liquidates. Also, pursuant to a business combination marketing agreement (the “Business Combination Marketing Agreement”) executed by NorthView, I -Bankersand Dawson James in connection with the IPO, and as amended on November7, 2022 and subsequently modified on January19, 2025, in connection with the signing of the Merger Agreement, I -Bankersand Dawson James are entitled to receive a